<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347473</url>
  </required_header>
  <id_info>
    <org_study_id>PTC08</org_study_id>
    <nct_id>NCT04347473</nct_id>
  </id_info>
  <brief_title>ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.</brief_title>
  <official_title>A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination With HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Pharmaceutical Industries Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with moderate-to-severe plaque psoriasis will receive Ilumya with or without Halog
      ointment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      25 adult subjects with moderate to severe plaque psoriasis will receive Ilumya 100mg
      subcutaneously at weeks 0, 4 and 16.

      At week 16, patients with remaining BSA ˃3% will be given HALOG ointment 0.1% to apply BID
      for 4 weeks. Patients who have ≤3% BSA at week 16 will remain on Ilumya monotherapy.

      Patients will continue to be evaluated at weeks 20 and 24.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body surface area</measure>
    <time_frame>16 weeks</time_frame>
    <description>evaluation of body surface area percentage affected by psoriasis where 1 palm is equivalent to 1%</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Ilumya</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilumya 100mg subcutaneous at weeks 0, 4 and 16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilumya Injectable Product</intervention_name>
    <description>IL-23 injection</description>
    <arm_group_label>Ilumya</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adult ≥ 18 years of age;

          2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis as defined by

               -  BSA 10%

               -  PGA ≥3

               -  PASI ≥12

          3. Must be a candidate for phototherapy and/or systemic therapy

          4. Females of childbearing potential (FCBP) must have a negative serum pregnancy test at
             Screening and negative urine pregnancy test at Baseline. FCBP who engage in activity
             in which conception is possible must use one of the approved contraceptive options:
             hormonal contraception; intrauterine device (IUD); tubal ligation; or partner's
             vasectomy; Male or female condom diaphragm with spermicide, cervical cap with
             spermicide, or contraceptive sponge with spermicide.

        Exclusion Criteria:

          1. Non-plaque forms of psoriasis

          2. Women of childbearing potential who are pregnant, intend to become pregnant, or are
             lactating

          3. Presence of significant uncontrolled medical condition that in the opinion of the
             investigator would affect patient safety during the trial.

          4. Active or untreated latent tuberculosis (TB)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerry Bagel, MD</last_name>
    <phone>6094434500</phone>
    <email>dreamacres1@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Nelson</last_name>
    <phone>6094434500</phone>
    <email>enelson@windsordermatology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Nelson</last_name>
      <phone>609-443-4500</phone>
      <phone_ext>1402</phone_ext>
      <email>enelson@windsordermatology.com</email>
    </contact>
    <investigator>
      <last_name>Jerry Bagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Nieves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexa Hetzel, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brianna Butler, PA-C</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wendy Myers, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

